Corcept Therapeutics Incorporated
CORT
Classifica tra le azioni
#1761
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Prezzo delle azioni
$112.72
Capitalizzazione di mercato
$12.18B
Variazione (1 giorno)
2.32%
Variazione (1 anno)
43.25%
Paese
US
Scambia Corcept Therapeutics Incorporated (CORT)
Categoria
Healthcare
Utile per Corcept Therapeutics Incorporated (CORT)
Utile nel Jun 2026 TTM: $26.37M
Secondo gli ultimi rapporti finanziari di Corcept Therapeutics Incorporated, gli utili attuali della società sono $26.37M. Nel 2023, la società ha registrato un utile di $124.56M, un aumento rispetto a agli utili del 2022, che erano di $116.19M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Corcept Therapeutics Incorporated dal 2001 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $26.37M | -83.67% |
| 2024 | $161.49M | 29.65% |
| 2023 | $124.56M | 7.20% |
| 2022 | $116.19M | -7.05% |
| 2021 | $125.01M | -5.01% |
| 2020 | $131.60M | 12.79% |
| 2019 | $116.68M | 26.61% |
| 2018 | $92.15M | 74.51% |
| 2017 | $52.81M | 548.72% |
| 2016 | $8.14M | -227.03% |
| 2015 | $-6.41M | -79.58% |
| 2014 | $-31.38M | -31.79% |
| 2013 | $-46.01M | 20.93% |
| 2012 | $-38.05M | 17.60% |
| 2011 | $-32.35M | 24.60% |
| 2010 | $-25.97M | 28.76% |
| 2009 | $-20.17M | 0.52% |
| 2008 | $-20.06M | 73.34% |
| 2007 | $-11.57M | -53.47% |
| 2006 | $-24.87M | 23.79% |
| 2005 | $-20.09M | -99.87% |
| 2004 | $-15.53B | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $1.35B | 5,019.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 4,470.06% |
HK
|
